Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both

In the phase III JAVELIN Ovarian 200 trial, 566 patients with platinum-resistant/refractory ovarian cancer were randomized 1:1:1 to receive avelumab alone, avelumab plus pegylated liposomal doxorubicin (PLD), or PLD alone. Cardiac monitoring was included for all patients. We report left ventricular...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonaca, Marc P, Moslehi, Javid J, Ledermann, Jonathan A, Michelon, Elisabete, Wei, Caimiao, Moran, Michael, Monk, Bradley J, Pujade-Lauraine, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546816/
https://www.ncbi.nlm.nih.gov/pubmed/37665777
http://dx.doi.org/10.1093/oncolo/oyad213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546816/
https://www.ncbi.nlm.nih.gov/pubmed/37665777
http://dx.doi.org/10.1093/oncolo/oyad213

Ejemplares similares